Biogen Inc. (NASDAQ: BIIB) has disclosed that its second-quarter 2026 results will include an acquired in-process research and development, upfront and milestone expense of approximately $164 million on a pre-tax basis, according to a company statement.

The charge is expected to reduce both GAAP and non-GAAP net income by approximately $0.95 per diluted share for the quarter ending June 30, 2026.

Biogen also anticipates a larger charge in the third quarter of 2026, with acquired in-process research and development, upfront and milestone expenses projected to range from approximately $290 million to $320 million. That charge relates to potential milestones and transactions that have not yet closed, and is expected to impact GAAP and non-GAAP net income per diluted share by approximately $1.75 to $1.95.

The company noted that such expenses, which cover upfront and milestone payments under collaboration and license agreements as well as premiums on equity securities and asset acquisitions, are not typically included in its forecasts due to the uncertain timing and magnitude of these transactions.

Biogen cautioned that second-quarter results have not been finalized and remain subject to financial statement closing procedures, with no assurance that final figures will match the preliminary estimates provided.